Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation - Wikidata - wikimedia - TriplyDB

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation

http://www.wikidata.org/entity/Q28276588

about

sameAs

Ghostwriting at elite academic medical centers in the United States What should be done to tackle ghostwriting in the medical literature?Citability of original research and reviews in journals and their sponsored supplements Reporting bias in medical research - a narrative review The haunting of medical journals: how ghostwriting sold "HRT"Industry sponsorship and research outcome Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy.Systematic review on the primary and secondary reporting of the prevalence of ghostwriting in the medical literature Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials Integrity in authorship and publication Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals Ghostwriting: the dirty little secret of medical publishing that just got bigger Professional medical organizations and commercial conflicts of interest: ethical issues Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints Industry Collaboration and Primary Guest Authorship of High-Impact Randomized Clinical Trials: A Cross-Sectional Study Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012 Who has used internal company documents for biomedical and public health research and where did they find them?SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials Vulnerability in clinical research with patients in pain: a risk analysis.Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?Outsourcing neuroimaging data analysis Implications for scientific accountability and issues in the public interest.The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.Editors, publishers, impact factors, and reprint income Authorship ethics in global health research partnerships between researchers from low or middle income countries and high income countries Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research.'Primum non nocere': A review of Taking America off Drugs: Why Behavioral Therapy is More Effective for Treating ADHD, OCD, Depression and Other Psychological Problems by Stephen Ray Flora.Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles.Integrity in scientific publishing Public perceptions of physician - pharmaceutical industry interactions: a systematic review.Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications.Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey.Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review Challenging medical ghostwriting in US courts.Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine.Knowledge of undisclosed corporate authorship ("ghostwriting") reduces the perceived credibility of antidepressant research: a randomized vignette study with experienced nurses.Investigator experiences with financial conflicts of interest in clinical trials.

P2860

Q21090130-4592C00D-A1CF-4BD1-842C-6CE092D1A6A0 Q21090135-ABD083E0-5698-4EE6-BC8D-DD56F2379CEE Q21091143-38B1DD3A-72C6-42F9-A894-D47DDABBAE4C Q21203744-AFB4ACE0-136A-47EF-9A68-39E5C4427BEF Q21563448-06AA8798-B795-4D50-87AB-7E5E278FBFF8 Q24202591-BFEB87DD-CFD7-4D84-BFAC-26245698E400 Q24289488-EFC01E92-C9D6-4289-A9FF-F9B5826F346F Q24561610-A6F25734-9537-4F33-991A-A60875AB6240 Q24604806-785F1223-08A9-4326-BA42-AE1A5BE0457E Q24614627-42D7550C-02CF-4B9E-A447-77235C68CA1D Q24643950-703AB38E-5ECA-4977-81DE-99A9DA60F3CC Q24644642-0ABC8B0F-9E0B-42A1-962D-A0AC4ADD227D Q28119336-4278D57D-A1E7-4EF5-A9F2-823F17F489C8 Q28288321-AE632525-C599-4519-91B5-9A5F92216DCF Q28475155-75D78C5E-BF45-4D2D-87C0-C59664C977F6 Q28475928-D5D46382-CEA3-4722-98AA-85B6C566A519 Q28477644-2C8FEA1E-B727-45C8-8BEA-AD72A98FCFC1 Q28548347-FB2A4625-8DE5-480E-AC8D-C848DAF17EEE Q28552890-CA399149-7429-489D-B082-1C87DF3211C9 Q28657906-29AA724A-AEA4-41FA-B1B8-4FDC03503373 Q28710019-62345D2A-4096-4333-99D5-BDED788202CB Q30431269-580AEBBB-84C9-4120-B151-2835160B494A Q33364538-AF5AB700-FF8B-4451-9BEE-BBDA779527ED Q33511695-C4866391-E34E-44B3-89F0-25C650580D74 Q33583631-5D3892C9-A740-4ECC-8989-65D17453E01F Q33737605-3B019FEC-FFC5-4054-9DEE-A1BDE06A45F7 Q33772338-7E9F71C0-E392-40B6-94A1-21D4BD1A562D Q33807895-36BC8CD6-8F15-4507-953E-BC9F7CDF347C Q33811019-01F8E9FB-A2CE-4A5E-9CA3-88AD0A97C64A Q33851285-A145549A-D32F-4694-81CF-380F5B438622 Q33874170-38D84CF1-5E03-431A-92ED-CF43C593970E Q33874709-EB93CF55-89B4-47E7-AE04-5F8C8DD2F447 Q33987346-10D1F4E9-4BE7-44AE-BA02-A2B3469A6154 Q34025773-E39213A7-11F4-433F-BAA4-8473070C78C8 Q34057966-07A93836-CE43-47AE-934E-72D76A789368 Q34105156-DE02AB73-0FC2-4C5D-BCE2-BD12EAD7153B Q34145613-BCB33A8A-F834-4305-99DA-25E9F1809BA6 Q34165083-B7FFB3AF-149D-4822-984A-8EBB94B8A67E Q34403714-892FD344-4669-48D2-A8C2-DD633C5DD5FE Q34540824-9BA0BCE2-EAD8-4673-B56E-D843392E39E6

P2860

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation

http://www.wikidata.org/entity/Q28276588

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@ast

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@en

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@nl

type

label

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@ast

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@en

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@nl

altLabel

Guest Authorship and Ghostwriting in Publications Related to Rofecoxib

@en

prefLabel

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@ast

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@en

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@nl

P1433

Q28276588-94319A42-E50B-43F5-A710-DBB4C99B89B1

P1476

Q28276588-67BAF71D-CC11-4F34-843A-8A8896B5697E

Q28276588-7D0388E1-D6B7-41F0-9DFA-9C2B402475DB

P2093

Q28276588-2281A761-6F16-4255-ACF6-AD1BE9E1C9A9

Q28276588-3F1BA915-CE24-4822-B125-E127AA6AFBAF

Q28276588-7F82EEC8-E345-4D1A-801B-58B600F7059C

Q28276588-F3F75E0B-8F3E-4E42-9AA9-D79CC7B368FE

Q28276588-FB9C5FEF-BFBF-4234-954A-83C41AF1701B

P304

Q28276588-5A4366DA-2BD5-4BEC-A0E1-967D49CEECCE

Q28276588-665D5D5B-B9DF-46B5-A97C-5CCCD92F377A

P31

Q28276588-4A5928EA-03AB-46BF-8C61-24B3FBCF9A03

P3181

Q28276588-46A053DD-2616-4125-B349-6916271BABC2

P356

Q28276588-A76CFF55-D032-4314-9BED-B5C3651D0826

P407

Q28276588-836FDD6E-272D-4585-8418-2DDBD45BA647

P433

Q28276588-2AD6C7D5-73CA-4512-A418-48D61ECA953D

P478

Q28276588-E44773AA-E273-4F9F-9450-ED9E676BF6F3

P50

Q28276588-00F7BE24-2592-4E66-8C36-2631D75457AA

Q28276588-1E2B9ABB-70CE-4EFB-A6F1-F641C4114C76

P577

Q28276588-8072662E-A406-4824-B18A-F5748F4387C4

P5875

Q28276588-F2B0017E-D991-40BE-AA77-8257E2F9AFCD

P698

Q28276588-8A35B2DE-FABD-4D9C-8266-737D22D790F0

P3181

P356

JAMA.299.15.1800

P1433

Journal of the American Medical Association

P1476

Guest Authorship and Ghostwriting in Publications Related to Rofecoxib

@en

Guest authorship and ghostwrit ...... ents from rofecoxib litigation

@en

P2093

David S Egilman

http://www.w3.org/2001/XMLSchema#string

David S. Egilman

http://www.w3.org/2001/XMLSchema#string

Joseph S. Ross

http://www.w3.org/2001/XMLSchema#string

Kevin P Hill

http://www.w3.org/2001/XMLSchema#string

Kevin P. Hill

http://www.w3.org/2001/XMLSchema#string

P304

1800

http://www.w3.org/2001/XMLSchema#string

1800-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

457152

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.299.15.1800

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

299

http://www.w3.org/2001/XMLSchema#string

P50

Harlan M. Krumholz

P577

2008-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5438567

http://www.w3.org/2001/XMLSchema#string

P698

18413874

http://www.w3.org/2001/XMLSchema#string